Adenosine

Generic Name: Adenosine

Brand Names: Adenocard, Viva-drops Lubricating Eye Drops

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 58-61-7

Unique Ingredient Identifier: K72T3FS567

Background: The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.

Adenosine was granted FDA approval on 30 October 1989.

Indication: Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions: Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)

Clinical Trials

Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients

Phase 3

Recruiting

Conditions: Supraventricular Tachycardia (SVtach)

Interventions: Drug: Adenosine
Drug: Verapamil Injection

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-13

Lead Sponsor: Rashid Latif Medical College

Target Recruit Count: 210

Registration Number: NCT06717685

Locations: 🇵🇰
Punjab Institute of Cardiology, Lahore, Punjab, Pakistan

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Phase 4

Recruiting

Conditions: Chronic Coronary Syndrome
Coronary Artery Disease
Ischemic Heart Disease

Interventions: Drug: Adenosine

First Posted Date: 2024-08-29

Last Posted Date: 2024-10-31

Lead Sponsor: Region Skane

Target Recruit Count: 180

Registration Number: NCT06578234

Locations: 🇸🇪
Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden

Cardiac Outcomes With Near-Complete Estrogen Deprivation

Not Applicable

Recruiting

Conditions: Triple Negative Breast Cancer
Cardiovascular Complications
Breast Cancer

Interventions: Drug: Adenosine Stress Cardiac Magnetic Resonance Imaging
Diagnostic Test: Electrocardiogram
Diagnostic Test: Computed Tomography Angiogram
Other: Laboratory Testing
Behavioral: Quality of Life Survey

First Posted Date: 2022-04-04

Last Posted Date: 2025-01-23

Lead Sponsor: Duke University

Target Recruit Count: 90

Registration Number: NCT05309655

Locations: 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC V8
Stage IVA Lung Cancer AJCC V8
Stage IVB Lung Cancer AJCC V8

Interventions: Drug: Adenosine A2B Receptor Antagonist PBF-1129
Procedure: Biospecimen Collection
Biological: Nivolumab

First Posted Date: 2022-02-10

Last Posted Date: 2025-03-21

Lead Sponsor: Dwight Owen

Target Recruit Count: 30

Registration Number: NCT05234307

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction

Phase 3

Withdrawn

Conditions: Myocardial Ischemia

Interventions: Drug: Adenosine

First Posted Date: 2021-08-20

Last Posted Date: 2024-05-17

Lead Sponsor: Vastra Gotaland Region

Registration Number: NCT05014061

Adrenaline for the Treatment of No-Reflow in Normotensive Patients

Phase 4

Completed

Conditions: No-Reflow Phenomenon
Acute Coronary Syndrome
Normotensive

Interventions: Drug: Adrenaline
Drug: Adenosine

First Posted Date: 2021-01-07

Last Posted Date: 2021-05-21

Lead Sponsor: National Institute of Cardiovascular Diseases, Pakistan

Target Recruit Count: 201

Registration Number: NCT04699110

Locations: 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

Phase 4

Recruiting

Conditions: Takotsubo Syndrome

Interventions: Other: Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
Drug: Apixaban 5 mg Oral Tablet
Drug: Adenosine
Drug: Dipyridamole 200 mg

First Posted Date: 2020-12-14

Last Posted Date: 2024-12-02

Lead Sponsor: Vastra Gotaland Region

Target Recruit Count: 1000

Registration Number: NCT04666454

Locations: 🇸🇪
Östersund Sjukhus, Östersund, Jämtland Härjedalen, Sweden
🇸🇪
Region Jönköpings Län, Jönköping, Region Jönköping, Sweden
🇸🇪
Norra Älvsborgs länssjukhus, Trollhättan, Västra Götalands Region, Sweden

and more 13 locations